Quarterly ResultMay 14, 2026, 04:08 PM
Sangamo Q1 Net Loss $31.0M; Revenue $1.4M; Nasdaq Delisting Appeal
AI Summary
Sangamo Therapeutics reported a Q1 2026 net loss of $31.0 million, or $0.08 per share, with revenues significantly decreasing to $1.4 million from $6.4 million in the prior year. The company continues its rolling Biologics License Agreement (BLA) submission for ST-920 for Fabry disease and is progressing its neurology pipeline, including ST-503 for chronic neuropathic pain and ST-506 for prion disease. Financially, Sangamo transitioned to the OTCQB Venture Market following a Nasdaq delisting and is appealing the decision, while also actively seeking additional funding to extend its cash runway beyond Q3 2026.
Key Highlights
- Sangamo reported Q1 2026 net loss of $31.0 million, compared to $30.6 million in Q1 2025.
- Diluted net loss per share was $0.08 in Q1 2026, down from $0.14 in Q1 2025.
- Revenues for Q1 2026 decreased to $1.4 million from $6.4 million in Q1 2025.
- Total GAAP operating expenses were $33.4 million, down from $36.1 million year-over-year.
- Cash and cash equivalents were $27.6 million as of March 31, 2026.
- Company estimates cash runway into Q3 2026, subject to securing additional funding.
- Rolling BLA submission for ST-920 (Fabry disease) is in progress, expected as early as summer 2026.
- Sangamo transitioned to OTCQB Venture Market and intends to appeal Nasdaq delisting determination on June 9, 2026.